Cite
MLA Citation
Salah-Eddin Al-Batran et al.. “Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.” Lancet oncology, vol. 17, no. 12, n.d., pp. 1697–1708. http://access.bl.uk/ark:/81055/vdc_100039385767.0x000032